ProPhase Labs (PRPH) Short Interest Ratio & Short Volume $0.39 -0.03 (-7.55%) Closing price 04:00 PM EasternExtended Trading$0.39 +0.00 (+1.14%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ProPhase Labs Short Interest DataProPhase Labs (PRPH) has a short interest of 4.42 million shares, representing 23.35% of the float (the number of shares available for trading by the public). This marks a 5,106.12% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.5, indicating that it would take 0.5 days of the average trading volume of 13.81 million shares to cover all short positions.Current Short Interest4,420,000 sharesPrevious Short Interest84,900 sharesChange Vs. Previous Month+5,106.12%Dollar Volume Sold Short$1.44 millionShort Interest Ratio0.5 Days to CoverLast Record DateFebruary 15, 2025Outstanding Shares23,874,000 sharesShort Percent of Float23.35%Today's Trading Volume2,745,799 sharesAverage Trading Volume13,810,813 sharesToday's Volume Vs. Average20% Short Selling ProPhase Labs? Sign up to receive the latest short interest report for ProPhase Labs and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPRPH Short Interest Over TimePRPH Days to Cover Over TimePRPH Percentage of Float Shorted Over Time ProPhase Labs Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/15/20254,420,000 shares $1.44 million +5,106.1%23.3%0.5 $0.33 1/31/202584,900 shares $22,354.17 -27.1%N/A0.1 $0.26 1/15/2025116,400 shares $69,851.64 +19.1%N/A0.4 $0.60 12/31/202497,700 shares $73,968.67 -10.5%N/A0.4 $0.76 12/15/2024109,200 shares $71,089.20 -24.6%N/A0.6 $0.65 11/30/2024144,900 shares $111,573.00 -41.0%N/A1 $0.77 11/15/2024245,700 shares $184,275.00 +59.4%N/A2.1 $0.75 10/31/2024154,100 shares $352,889.00 -25.2%N/A1.9 $2.29 10/15/2024206,100 shares $471,969.00 -10.8%N/A7.1 $2.29 9/30/2024231,000 shares $559,020.00 -9.9%N/A7.7 $2.42 Get the Latest News and Ratings for PRPH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. 9/15/2024256,300 shares $627,935.00 +3.0%N/A8.1 $2.45 8/31/2024248,900 shares $669,541.00 -9.9%N/A8.4 $2.69 8/15/2024276,300 shares $624,438.00 -13.3%N/A8.5 $2.26 7/31/2024318,500 shares $974,610.00 +0.7%N/A9.4 $3.06 7/15/2024316,400 shares $1.02 million -1.8%N/A8.6 $3.22 6/30/2024322,300 shares $1.35 million +0.5%N/A5.4 $4.18 6/15/2024320,800 shares $1.47 million +2.1%N/A5.3 $4.59 5/31/2024314,200 shares $1.62 million +20.8%N/A5.2 $5.15 5/15/2024260,100 shares $1.34 million -1.9%N/A4.3 $5.14 4/30/2024265,100 shares $1.22 million -3.5%1.9%5 $4.61 4/15/2024274,700 shares $1.69 million +6.8%2.0%5.5 $6.16 3/31/2024257,300 shares $1.66 million +3.7%1.8%9.6 $6.47 3/15/2024248,200 shares $1.25 million -16.9%1.8%9.5 $5.04 2/29/2024298,500 shares $1.33 million +0.7%2.1%11.2 $4.47 2/15/2024296,400 shares $1.47 million -0.2%2.1%12.1 $4.96 1/31/2024297,000 shares $1.44 million +4.7%2.1%11.2 $4.85 1/15/2024283,600 shares $1.39 million -7.3%2.0%10.9 $4.90 12/31/2023306,000 shares $1.38 million -5.1%2.2%12.2 $4.52 12/15/2023322,400 shares $1.45 million -20.2%2.3%13.1 $4.50 11/30/2023404,000 shares $2.05 million +45.5%2.9%15.2 $5.07 11/15/2023277,700 shares $1.21 million -5.3%2.0%8.8 $4.35 10/31/2023293,100 shares $1.29 million -1.9%2.3%7.9 $4.39 10/15/2023298,800 shares $1.31 million -3.9%2.3%7.7 $4.37 9/30/2023311,000 shares $1.36 million +0.2%2.4%7.5 $4.37 9/15/2023310,300 shares $1.41 million -13.8%2.4%7.1 $4.56 8/31/2023360,100 shares $1.54 million +0.5%2.8%7.1 $4.28 8/15/2023358,300 shares $2.04 million +0.3%2.8%6.3 $5.70 7/31/2023357,200 shares $2.60 million +8.9%2.7%5.9 $7.28 7/15/2023327,900 shares $2.33 million +1.1%2.5%4.5 $7.11 6/30/2023324,400 shares $2.36 million +1.8%2.5%4.3 $7.26Elon’s “New Gold” (Ad)MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.I reveal all of the details here. 6/15/2023318,700 shares $2.38 million -8.1%2.4%4.1 $7.47 5/31/2023346,700 shares $3.29 million +2.5%2.6%4.7 $9.49 5/15/2023338,400 shares $2.72 million -4.1%2.6%5.6 $8.04 4/30/2023352,700 shares $2.65 million -7.9%2.7%6.8 $7.50 4/15/2023382,800 shares $3.12 million +23.5%2.9%8.5 $8.16 3/31/2023309,900 shares $2.36 million +17.9%2.4%6.6 $7.62 3/15/2023262,900 shares $2.12 million -10.0%2.2%5.2 $8.06 2/28/2023292,000 shares $2.13 million -3.3%2.4%5.9 $7.31 2/15/2023301,900 shares $2.42 million -6.0%2.5%5.6 $8.01 1/31/2023321,200 shares $2.63 million -8.7%2.6%4.9 $8.18 1/15/2023351,700 shares $3.29 million -5.8%2.8%5 $9.36 12/30/2022373,300 shares $3.59 million -9.6%2.9%4.8 $9.63 12/15/2022412,700 shares $4.20 million +10.1%3.2%5.1 $10.18 11/30/2022375,000 shares $3.89 million -11.9%3.0%4.3 $10.37 11/15/2022425,800 shares $5.03 million +16.2%3.4%4.5 $11.81 10/31/2022366,400 shares $4.42 million -21.1%2.9%3.5 $12.05 10/15/2022464,400 shares $4.83 million +13.9%3.7%4 $10.41 9/30/2022407,700 shares $4.60 million +28.9%3.2%2.7 $11.28 9/15/2022316,300 shares $3.38 million -4.2%2.5%1.8 $10.68 8/31/2022330,300 shares $4.00 million -9.8%2.6%1.8 $12.11 8/15/2022366,300 shares $4.47 million +31.6%3.0%1.9 $12.19 7/31/2022278,300 shares $2.88 million -2.7%3.3%1.7 $10.34 7/15/2022286,000 shares $4.00 million +22.8%3.4%1.9 $13.98 6/30/2022232,900 shares $2.95 million +61.4%2.8%2.2 $12.68 6/15/2022144,300 shares $1.53 million +65.3%1.7%2 $10.61 5/31/202287,300 shares $790,065.00 -1.0%0.7%1.7 $9.05 5/15/202288,200 shares $620,046.00 +2.3%0.7%2.7 $7.03 4/30/202286,200 shares $639,604.00 +21.4%0.7%3.2 $7.42 4/15/202271,000 shares $590,010.00 -31.2%0.6%2.8 $8.31 3/31/2022103,200 shares $722,400.00 +1.7%0.8%4.5 $7.00 3/15/2022101,500 shares $652,645.00 -1.4%0.8%5 $6.43 2/28/2022102,900 shares $650,328.00 +12.2%0.8%3.7 $6.32 2/15/202291,700 shares $633,647.00 -19.8%0.7%2.6 $6.91 1/31/2022114,300 shares $827,532.00 +13.5%0.9%3 $7.24 1/15/2022100,700 shares $735,110.00 -20.1%0.8%2.4 $7.30 12/31/2021126,000 shares $903,420.00 +17.4%1.0%2.5 $7.17 12/15/2021107,300 shares $743,589.00 -29.8%0.8%2.1 $6.93 11/30/2021152,800 shares $959,584.00 -10.2%1.2%2.9 $6.28 11/15/2021170,100 shares $1.02 million -10.1%1.3%3.6 $6.00 10/29/2021189,100 shares $1.11 million -9.6%1.5%2.8 $5.89 10/15/2021209,100 shares $1.19 million -13.3%1.7%2.3 $5.70 9/30/2021241,300 shares $1.25 million -7.0%1.9%2.3 $5.20 9/15/2021259,500 shares $1.28 million -14.1%2.1%1.5 $4.95 8/31/2021302,100 shares $1.62 million -5.6%2.4%0.9 $5.36 8/13/2021320,000 shares $2.07 million -17.6%2.6%0.9 $6.46 7/30/2021388,500 shares $2.78 million -7.0%3.1%1.1 $7.16 7/15/2021417,900 shares $2.57 million -9.0%3.4%1.3 $6.15 6/30/2021459,100 shares $2.85 million +42.2%3.7%1.3 $6.20 6/15/2021322,800 shares $1.90 million +69.6%2.6%0.8 $5.90 5/28/2021190,300 shares $913,440.00 -12.3%1.5%0.5 $4.80Elon’s “New Gold” (Ad)MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.I reveal all of the details here. 5/14/2021217,000 shares $1.21 million +17.5%1.7%0.8 $5.56 4/30/2021184,700 shares $971,522.00 +39.8%1.5%0.7 $5.26 4/15/2021132,100 shares $696,167.00 -24.2%1.1%0.4 $5.27 3/31/2021174,300 shares $1.09 million +42.8%1.4%0.5 $6.27 3/15/2021122,100 shares $880,341.00 +62.8%1.0%0.6 $7.21 2/26/202175,000 shares $579,000.00 -24.8%0.6%0.4 $7.72 2/12/202199,700 shares $1.04 million -11.0%0.8%0.6 $10.41 1/29/2021112,000 shares $1.09 million +31.0%1.0%0.7 $9.76 1/15/202185,500 shares $1.37 million No Change0.7%0.5 $15.99 PRPH Short Interest - Frequently Asked Questions What is ProPhase Labs' current short interest? Short interest is the volume of ProPhase Labs shares that have been sold short but have not yet been covered or closed out. As of February 15th, traders have sold 4,420,000 shares of PRPH short. 23.35% of ProPhase Labs' shares are currently sold short. Learn More on ProPhase Labs' current short interest. Which institutional investors are shorting ProPhase Labs? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ProPhase Labs: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for ProPhase Labs? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.35% of ProPhase Labs' floating shares are currently sold short. Is ProPhase Labs' short interest increasing or decreasing? ProPhase Labs saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 4,420,000 shares, an increase of 5,106.1% from the previous total of 84,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ProPhase Labs' short interest compare to its competitors? 23.35% of ProPhase Labs' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ProPhase Labs: Iterum Therapeutics plc (5.50%), Reviva Pharmaceuticals Holdings, Inc. (17.45%), Outlook Therapeutics, Inc. (14.96%), Estrella Immunopharma, Inc. (0.05%), PDS Biotechnology Co. (11.43%), Immix Biopharma, Inc. (2.38%), Connect Biopharma Holdings Limited (0.07%), OncoCyte Co. (2.16%), Prelude Therapeutics Incorporated (11.39%), Kezar Life Sciences, Inc. (1.94%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($25.81 billion), iShares 20+ Year Treasury Bond ETF ($10.38 billion), MicroStrategy Incorporated ($7.74 billion), AppLovin Co. ($6.32 billion), Apollo Global Management, Inc. ($5.97 billion), Super Micro Computer, Inc. ($4.89 billion), Charter Communications, Inc. ($4.52 billion), Capital One Financial Co. ($3.94 billion), Schlumberger Limited ($3.19 billion), and Reddit, Inc. ($3.01 billion). View all of the most shorted stocks. What does it mean to sell short ProPhase Labs stock? Short selling PRPH is an investing strategy that aims to generate trading profit from ProPhase Labs as its price is falling. PRPH shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ProPhase Labs? A short squeeze for ProPhase Labs occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PRPH, which in turn drives the price of the stock up even further. How often is ProPhase Labs' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PRPH, twice per month. The most recent reporting period available is February, 15 2025. More Short Interest Resources from MarketBeat Related Companies Iterum Therapeutics Short Interest Data Reviva Pharmaceuticals Short Interest Data Outlook Therapeutics Short Interest Data Estrella Immunopharma Short Interest Data PDS Biotechnology Short Interest Data Immix Biopharma Short Interest Data Connect Biopharma Short Interest Data OncoCyte Short Interest Data Prelude Therapeutics Short Interest Data Kezar Life Sciences Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PRPH) was last updated on 3/4/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
